title: Missed doses of oral antihyperglycemic medications in US adults with type 2 diabetes mellitus: prevalence and self-reported reasons.
abstract: Adherence to antihyperglycemic medication is thought to be suboptimal, but the proportion of patients missing doses, the number of doses missed, and reasons for missing are not well described. This survey was conducted to estimate the prevalence of and reasons for missed doses of oral antihyperglycemic medications among US adults with type 2 diabetes mellitus, and to explore associations between missed doses and health outcomes.
  
  
  
  The study was a cross-sectional patient survey. Respondents were contacted via a commercial survey panel and completed an on-line questionnaire via the Internet. Respondents provided information about their use of oral antihyperglycemic medications including doses missed in the prior 4 weeks, personal characteristics, and health outcomes. Weights were calculated to project the prevalence to the US adult population with type 2 diabetes mellitus. Outcomes were compared according to number of doses missed in the past 4 weeks using bivariate statistics and generalized linear models.
  
  
  
  Approximately 30% of adult patients with type 2 diabetes mellitus reported missing or reducing ≥1 dose of oral antihyperglycemic medication in the prior 4 weeks. Accidental missing was more commonly reported than purposeful skipping, with forgetting the most commonly reported reason. The timing of missed doses suggested respondents had also forgotten about doses missed, so the prevalence of missed doses is likely higher than reported. Outcomes were poorer among those who reported missing three or more doses in the prior 4 weeks.
  
  
  
  A substantial number of US adults with type 2 diabetes mellitus miss doses of their oral antihyperglycemic medications.
authors.affiliation: a Kantar Health , Horsham , PA , USA ;
authors.forename: Jeffrey T
authors.initials: JT
authors.lastname: Vietri
authors.affiliation: b Merck & Co. , Upper Gwynedd , PA , USA ;
authors.forename: Catherine S
authors.initials: CS
authors.lastname: Wlodarczyk
authors.affiliation: c Kantar Health , New York , NY , USA.
authors.forename: Rose
authors.initials: R
authors.lastname: Lorenzo
authors.affiliation: b Merck & Co. , Upper Gwynedd , PA , USA ;
authors.forename: Swapnil
authors.initials: S
authors.lastname: Rajpathak
mesh_terms: D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D057566:Self Report; D014481:United States / Q000453:epidemiology; D016903:Drug Monitoring
chemical_list: D007004:Hypoglycemic Agents
keywords: Adherence; Disease management; Oral; Quality of life; Type 2 diabetes